Takara Bio Offers Drug For Treatment Of Chronic Lymphatic Leukemia

[Guest guest]

BlankTakara Bio Offers Drug For Treatment Of Chronic Lymphatic Leukemia

10 Sep 2006

Takara Bio Inc., a forerunner in cancer treatment, has offered its RetroNectin

for the treatment chronic lymphatic leukemia in phase-I clinical trials

currently being conducted at the U.S. Memorial Sloan-Kettering Cancer Center

(MSKCC).

The clinical trial targets 30 patients and will take about two to three years to

complete.

This new approach of gene treatment using RetroNectin has been performed in 40

institutions around the world.

By Aki Tsukioka, JCN Staff Writer

Article URL:

http://www.medicalnewstoday.com/medicalnews.php?newsid=51517